Lercamed

Lercanidipine Hydrochloride, the active ingredient in Lercamed, is a calcium channel blocker (dihydropyridine) presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adults with hypertension.

GNH USA supplies Lercamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Lercamed is manufactured under EU Good Manufacturing Practice and is available for bulk and unit‑dose procurement.

Lercamed, a calcium channel blocker, is indicated for conditions related to elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: helps control high systolic pressure in elderly patients. - Secondary hypertension (as adjunct therapy): may be added to other antihypertensives to achieve adequate blood pressure control.

Lercamed may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring after dose initiation. - Flushing: transient warmth and reddening of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: rapid swelling of face, lips, tongue or airway. - Hepatic dysfunction: abnormal liver enzyme elevations requiring monitoring.

When prescribing Lercamed, clinicians should consider the following precautions to ensure safe use. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; liver function tests should be performed periodically. - Concomitant strong CYP3A4 inhibitors: may increase plasma levels, requiring dose adjustment or avoidance. - Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Elderly patients: increased susceptibility to hypotension and dizziness; start at low dose and monitor. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lercamed can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase Lercanidipine concentrations. - Grapefruit juice: can elevate drug exposure and increase risk of hypotension.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood pressure‑lowering effect may cause excessive hypotension. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Lercanidipine levels, diminishing therapeutic effect. - Simvastatin: increased risk of statin‑related muscle toxicity when combined.